



Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Submit this form 1449/PTO

# **INFORMATION DISCLOSURE STATEMENT BY APPLICANT**

(Use as many sheets as necessary)

## **Complete if Known**

Application Number	10/589,116
Filing Date	August 11, 2006
First Named Inventor	SOREQ, Hermona et al.
Art Unit	1656
Examiner Name	S. Noakes
Attorney Docket Number	7640-X06-063

Sheet 1 of 8

## **NON PATENT LITERATURE DOCUMENTS**

Examiner Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>
	AA	ABO, T. and KAWAMURA, T., Ther. Apher., 2002, pp.348-357, vol.6.	
	AB	ABRAMSON, N. and MELTON, B., Am. Fam. Physician, 2000, pp.2053-2060., vol.62.	
	AC	BASSER, R.L. et al., Blood, 2002, pp.2599-2602, vol.99.	
	AD	BASSINI, A. et al., Blood, 1999, pp.1178-1188, vol.93.	
	AE	BIRIKH, K.R. et al, RNA Society, 1997, pp.429-437, vol.3.	
	AF	BOROVIKOVA, L.V. et al., Nature, 2000, pp.458-462, vol.405.	
	AG	BRENNER et al., FASEB J, 2003, pp.214-22, vol.17(2).	
	AH	BUSSLINGER, M., Ann. Rev. Immunol., 2004, pp.55-79, vol.22.	
	AI	CHAN, R.Y.Y. et al., J. Biol. Chem., 1998, pp.9727-9733, vol.273.	
	AJ	CRAIG, W. et al., Br. J. Haematol, 1994, pp.24-30, vol.88.	

Examiner Signature	Date Considered
--------------------	-----------------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 608. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /S.M.N./

Substitute for form 1449/PTO

# INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

## Complete if Known

Application Number	10/589,116
Filing Date	Feb 10, 2005
First Named Inventor	SOREQ, Hermona et al.
Art Unit	
Examiner Name	
Attorney Docket Number	7640-X06-063

Sheet 2

of

8

## NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>
	AK	DELGADO, I. et al., Gynecol. Obstet. Invest., 1994, pp.227-235, vol.38.	
	AL	DEUTSCH, V. et al., Exp. Hematol., 2002, pp.1153-1161, vol.30.	
	AM	ERB, C. et al., J. Neurochem., 2001, pp.638-646, vol.77.	
	AN	FLORES-FLORES, C. et al., J. Neural Transm., 2002, pp.165-179, vol.62(supp).	
	AO	GAINSFORD, T. et al., Blood, 2000, pp.528-534, vol.95.	
	AP	GRISARU, D. et al., Mol. Cell Biol., 1999, pp.788-795, vol.19.	
	AQ	GRISARU, D. et al., Molecular Medicine, 2001, pp.93-105, vol.7.	
	AR	GUENECHEA, G. et al., Blood, 1999, pp.1097-1105, vol.93.	
	AS	HANADA and YOSHIMURA, Cytokine Growth Factor Rev., 2002, pp.413-421, vol.13.	
	AT	HELLSTROM-LINDAHL, E. and NORDBERG, A., J. Neuroimmunol., 1996, pp.139-144, vol.68.	

Examiner Signature	Date Considered
--------------------	-----------------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

1 Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /S.M.N./

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  <i>(Use as many sheets as necessary)</i>		<b>Complete if Known</b>	
		Application Number	10/589,116
		Filing Date	August 11, 2006
		First Named Inventor	SOREQ, Hermona et al.
		Art Unit	
		Examiner Name	
Sheet 3	of 8	Attorney Docket Number	7640-X06-063

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>
	AU	ISHIBASHI, T. et al., Proc. Natl. Acad. Sci. U.S.A., 1989, pp.5953-5957, vol.86.	
	AV	JACKSON, C.W., Blood, 1973, pp.413-421, vol.42.	
	AW	JOHNSON, B. et al., Anal. Biochem., 1991, pp.268-77, vol.198.	
	AX	KANAMARU, S. et al, Stem Cells, 2000, pp.190-195, vol.18.	
	AY	KASER, A. et al., Blood, 2001, pp.2720-2725, vol.98.	
	AZ	KAWASHIMA, K. and FUJI, T., Pharmacol Ther., 2000, pp.29-48, vol.86.	
	BA	KIECOLT-GLASER, J.K. et al., Proc. Natl. Acad. Sci. U.S.A., 2003, pp.9090-9095, vol.100.	
	BB	KUTER, D.J., Transfusion, 2002, pp.279-283, vol.42.	
	BC	LAGASSE, E. and WEISSMAN, I.L., J. Immunol. Methods, 1996, pp.139-150, vol.197.	
	BD	LEV-LEHMAN, E. et al., Blood, 1997, pp.3644-3653, vol.89.	

Examiner Signature	Date Considered
--------------------	-----------------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /S.M.N./

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO

**INFORMATION DISCLOSURE  
STATEMENT BY APPLICANT**

(Use as many sheets as necessary)

**Complete if Known**

Application Number	10/589,116
Filing Date	August 11, 2006
First Named Inventor	SOREQ, Hermona et al.
Art Unit	
Examiner Name	
Attorney Docket Number	7640-X06-063

Sheet 4

of

8

**NON PATENT LITERATURE DOCUMENTS**

Examiner Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>
	BE	LI, K. et al., Br. J. Haematol., 1999, pp.178-185, vol.104.	
	BF	LI, Y. et al., J. Neurosci., 2000, pp.149-155, vol.20.	
	BG	MARCHISIO, M. et al., Anat. Rec., 1999, pp.7-14, vol.255.	
	BH	MASTORAKOS, G. and ILIAS, I., Ann. NY Acad. Sci., 2000, pp.95-106, vol.900.	
	BI	MILLER, G.E. et al., Health Psychol., 2002, pp.531-41, vol.21.	
	BJ	MITA, Y. et al., Eur. J. Pharmacol., 1996, pp.121-127, vol.297.	
	BK	NAGATA, Y. et al., Thromb. Haemost., 1997, pp.808-814, vol.77.	
	BL	NAKASHIMA, K. et al., Semin Hematol., 1998, pp.210-221, vol.35.	
	BM	NITSCHKE, A. et al., Haematologica, 2001, pp.693-699, vol.86.	
	BN	OSHEVSKI, S. et al., Biochem. Biophys. Res. Commun., 1999, pp.603-609, vol.263.	

Examiner Signature	Date Considered
--------------------	-----------------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /S.M.N./

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO

# **INFORMATION DISCLOSURE STATEMENT BY APPLICANT**

(Use as many sheets as necessary)

## **Complete if Known**

Application Number	10/589, 116
Filing Date	August 11, 2006
First Named Inventor	SOREQ, Hermona et al.
Art Unit	
Examiner Name	
Attorney Docket Number	7640-X06-063

Sheet 5 of 8

## **NON PATENT LITERATURE DOCUMENTS**

Examiner Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>
	BO	PERRY, C. et al., Neoplasia, 2004, pp.279-86, vol.6(3).	
	BP	PICK, M. et al., Br. J. Haematol., 1998, pp.639-650, vol.103.	
	BQ	PICK, M. et al., Ann. NY Acad. Sci., 2004, pp.85-95, vol.1018.	
	BR	PICK, M. et al., Exp. Hematol., 2002, p.1079, vol.30.	
	BS	PORCELLINI, A. et al., Int. J. Cell Cloning, 1983, pp.92-104, vol.1.	
	BT	RACKE, F.K. et al., J. Biol. Chem., 2001, pp.522-528, vol.276.	
	BU	REIZENSTEIN, P., Br. J. Haematol., 1979, pp.329-334, vol.43.	
	BV	ROJNUCKARIN, P. et al., Blood, 2001, pp.154-161, vol.97.	
	BW	ROJNUCKARIN, P. et al., J. Biol. Chem., 2001, pp.41014-41022, vol.276.	
	BX	SKLAN, E.H. et al., Proc. Natl. Acad. Sci. U.S.A., 2004, pp.5512-5517, vol.101(15).	

Examiner Signature	Date Considered
--------------------	-----------------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> Applicant is to place a check mark here if English language Translation is attached.  
This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /S.M.N./

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO

# **INFORMATION DISCLOSURE STATEMENT BY APPLICANT**

(Use as many sheets as necessary)

## **Complete if Known**

Application Number	10/589,116
Filing Date	August 11, 2006
First Named Inventor	SOREQ, Hermona et al.
Art Unit	
Examiner Name	
Attorney Docket Number	7640-X06-063

Sheet 6 of 8

## **NON PATENT LITERATURE DOCUMENTS**

Examiner Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>
	BY	SOREQ, H. and SEIDMAN, S., Nat. Rev. Neurosci., 2001, pp.294-302, vol.2.	
	BZ	STERNFELD, M. et al., J. Neurosci., 1998, pp.1240-1249, vol.18.	
	CA	STERNFELD, M. et al., J. Physiol. Paris, 1998, pp.249-255, vol.92.	
	CB	STERNFELD, M. et al., Proc. Natl. Acad. Sci. U.S.A., 2000, pp.8647-8652, vol.97.	
	CC	STOWE, R. P. et al., J. Leukoc. Biol., 1999, pp.179-186, vol.65.	
	CD	SZELENYI et al., Immunol. Letter, 1987, pp.49-54, vol.16.	
	CE	SZELENYI et al., Br. J. Haematol., 1982, pp.241-5, vol.50.	
	CF	TAVASSOLI, M., Blood Cells, 1991, pp.269-281, vol.17.	
	CG	TERAMURA, M. et al., Cancer Chemother. Pharmacol., 1996, pp.S99-102, vol.38(supp).	
	CH	TOFT, P. et al., Apmis, 1994, pp.43-48, vol.102.	

Examiner Signature	Date Considered
--------------------	-----------------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /S.M.N./

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO

# **INFORMATION DISCLOSURE STATEMENT BY APPLICANT**

(Use as many sheets as necessary)

**Complete if Known**

Application Number	10/589,116
Filing Date	August 11, 2006
First Named Inventor	SOREQ, Hermona et al.
Art Unit	
Examiner Name	
Attorney Docket Number	7640-X06-063

Sheet 7

of

8

## **NON PATENT LITERATURE DOCUMENTS**

Examiner Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>
	CI	TOPIKO and CAILLOU, Blood, 1985, pp.891-5, vol.66.	
	CJ	TRACEY, K.J., Nature, 2002, pp.853-9, vol.420.	
	CK	TUIMALA, R. et al., Br. J. Obstret. Gynecol., 1976, pp.707-710, vol.83.	
	CL	WANAHTA, A. et al., Clin. Infect. Dis., 2002, pp.1585-1592, vol.34.	
	CM	WANG, H. et al., Nature, 2003, pp.384-388, vol.421.	
	CN	WILSON et al., J. Am. Geriatr. Soc., 2002, pp.2041-2056, vol.50.	
	CO	XU, Z. and WEISS, A., Nat. Immunol., 2002, pp.764-71, vol.3.	
	CP	ZAHOREC, R., Bratisl. Lek. Listy., 2001, pp.5-14, vol.102.	
	CQ	ZHANG, X.J. et al., Cell Death Differ., 2002, pp.790-800, vol.9.	
	CR	DEUTSCH, V. et al., Blood, 2001, p. 73a, vol91 (11 - part1).	

Examiner Signature	Date Considered
--------------------	-----------------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /S.M.N./

**Complete if Known**

<b>Application Number</b>	10/589,116
<b>Filing Date</b>	August 11, 2006
<b>First Named Inventor</b>	SOREQ, Hermona et al.
<b>Art Unit</b>	1656
<b>Examiner Name</b>	S. Noakes
<b>Attorney Docket Number</b>	7640-X06-063

Sheet 8

8

2

8

Attorney Docket Number

7640-X06-063

[illegible]

Examiner  
Signature

/Suzanne M. Noakes/

Date  
Considered

12/18/2009

1 Applicant's unique citation designation number (optional). 2 Applicant is to place a check here if English language Translation is attached. This collection of information is required by 37 CFR 198. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you spend completing this form should be sent to the Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. Do not send fees or completed forms to this address. Send to: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /S.M.N./